Skip to main content
SCANCELL HOLDINGS PLC logo

SCANCELL HOLDINGS PLC — Investor Relations & Filings

Ticker · SCLP ISIN · GB00B63D3314 LEI · 2138008RXEG856SNP666 IL Professional, scientific and technical activities
Open in API
Filings indexed 436 across all filing types
Latest filing 2020-04-29 Regulatory Filings
Country GB United Kingdom
Listing IL SCLP

About SCANCELL HOLDINGS PLC

https://www.scancell.co.uk/

Scancell Holdings PLC is a clinical-stage company developing novel active immunotherapies for the treatment of cancer. Its approach focuses on enhancing long-lasting, tumor-specific immunity to address significant unmet needs in oncology, particularly for hard-to-treat cancers. The company leverages its proprietary technology platforms, Immunobody®, Moditope®, and AvidiMab™, to create targeted, off-the-shelf therapies. The Immunobody® platform generates DNA-based immunotherapies, with its lead candidate, iSCIB1+, targeting advanced melanoma. The Moditope® platform develops peptide-based therapies, with a lead product showing encouraging Phase 2 data in a broad range of solid tumors. Scancell aims to deliver treatments that are safe, effective, easily administered, and accessible to patients.

Recent filings

Filing Released Lang Actions
Second Price Monitoring Extn
Regulatory Filings Classification · 99% confidence The document is very short (1380 characters) and begins with 'RNS Number : 3622L', indicating it is a regulatory news service announcement from the London Stock Exchange. The content discusses a 'Second Price Monitoring Extension' for a security, which is a specific operational notice related to trading halts or volatility controls. This type of miscellaneous, time-sensitive regulatory announcement that doesn't fit the specific financial report categories (like 10-K, ER, IR) is best classified under the general regulatory filing/announcement category.
2020-04-29 English
Price Monitoring Extension
Regulatory Filings Classification · 99% confidence The document is very short (1363 characters) and begins with 'RNS Number : 3612L', indicating it is a regulatory news service announcement from the London Stock Exchange. The content discusses a 'Price Monitoring Extension' for a security, which is a specific operational notice related to trading mechanisms, not a comprehensive financial report (like 10-K or IR) or a standard corporate action (like DIV or ER). Since it is a general regulatory announcement that doesn't fit the highly specific categories like AGM-R, 10-K, ER, or DIV, the most appropriate fallback category is Regulatory Filings (RNS).
2020-04-29 English
Director Dealing
Director's Dealing Classification · 100% confidence The document is an official announcement disseminated via the RNS (Regulatory News Service) number 1454L, dated April 28, 2020. The core content explicitly details a 'Director Dealing' transaction where a person closely associated with a Non-Executive Director sold a significant number of ordinary shares. This perfectly matches the definition of a Director's Dealing report (insider trade notification). The structure, including the mandatory notification tables required for such disclosures, confirms this classification. It is not a general regulatory filing (RNS) because it fits a more specific category.
2020-04-28 English
Director Dealing
Director's Dealing Classification · 100% confidence The document begins with an 'RNS Number' and the date, indicating it is a regulatory announcement via the London Stock Exchange's RNS service. The core content is titled 'Director Dealing' and details the sale of shares by a person closely associated with a Non-Executive Director (Vulpes Life Science Fund associated with Martin Diggle). This directly matches the definition of 'Director's Dealing' (insider trades). The specific filing category for this is 'DIRS'. Although it is distributed via RNS, the specific content dictates the DIRS classification over the general RNS fallback.
2020-04-27 English
Second Price Monitoring Extn
Regulatory Filings Classification · 99% confidence The document is very short (1380 characters) and contains the header 'RNS Number : 8458K'. It announces a 'Second Price Monitoring Extension' related to trading activity on the London Stock Exchange. This is a routine, brief regulatory announcement concerning market operations rather than a comprehensive financial report (like 10-K or IR) or a specific corporate action like a dividend or management change. Given the RNS header and the nature of the announcement (trading mechanism update), the most appropriate classification is the general regulatory announcement fallback category.
2020-04-24 English
Price Monitoring Extension
Regulatory Filings Classification · 99% confidence The document is very short (1363 characters) and begins with 'RNS Number : 8451K', indicating it is a regulatory news service announcement from the London Stock Exchange. The content discusses a 'Price Monitoring Extension' for a security, which is a routine market operational update rather than a comprehensive financial report (like 10-K or IR) or a specific corporate action announcement (like DIV or CAP). Since it is a general regulatory announcement that doesn't fit the highly specific categories, the most appropriate fallback is 'Regulatory Filings' (RNS).
2020-04-24 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.